FDA Approves Sonrotoclax for Mantle Cell Lymphoma
May 22, 2026
On May 13, 2026, the FDA approved sonrotoclax (Beqalzi from BeOne), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL).
On May 13, 2026, the FDA approved sonrotoclax (Beqalzi from BeOne), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL).
In an analysis of previous trials, CAR-T therapy showed moderate efficacy in patients with CLL, but questions remain about the durability of responses.
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.
CLL cells express PD-1 when actively growing, and increased PD-1 expression may be an early sign of resistance to BTK inhibitor therapy.
During a 30-minute phone call, individuals have the opportunity to ask questions and get honest input from a fellow patient who has been through it before.
Patients with chronic lymphocytic leukemia (CLL) have an impaired immune system, which leads to a reduced ability to fight infections and other diseases.
Chronic lymphocytic leukemia (CLL) patients with abnormal bone health are at high risk for fragility fractures, which can occur with minimal trauma.
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of a type of white blood cell called B-lymphocytes.
A newly published paper in Clinical Cancer Research found that when patients successfully treated with fixed-duration ibrutinib-venetoclax developed progressive disease, they had no acquired resistance mutations in BTK, BCL2, or PLCG2.